RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells

Boyang Shi,Ke An,Yueqin Wang,Yuhan Fei,Caixia Guo,Qiangfeng Cliff Zhang,Yun-Gui Yang,Xin Tian,Quancheng Kan
DOI: https://doi.org/10.1016/j.gpb.2022.10.006
2022-11-01
Abstract:Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) positively affect the initial control ratio of non-small cell lung cancer (NSCLC). Rapidly acquired resistance to EGFR-TKI is a major hurdle in successful treatment. However, the mechanisms that control the resistance of EGFR-TKI remain largely unknown. RNA structures have widespread and crucial functions in many biological regulations, however, the functions of RNA structures in regulating cancer drug resistance remain unclear. Here, the psoralen analysis of RNA interactions and structures method (PARIS) is used to establish the higher-order RNA structure maps of EGFR-TKI resistant and sensitive cells of NSCLC. Our results show RNA structural regions are enriched in untranslation regions (UTRs) and correlate with translation efficiency (TE). Moreover, yrdC N<sup>6</sup>-threonylcarbamoyltransferase domain containing (YRDC) promotes resistance to EGFR-TKI. RNA structure formation in YRDC 3' UTR suppresses embryonic lethal abnormal vision-like 1 (ELAVL1) binding, leading to EGFR-TKI sensitivity by impairing YRDC translation. A potential cancer therapy strategy is provided by using antisense oligonucleotide (ASO) to perturb the interaction between RNA and protein. Our study reveals an unprecedented mechanism through which the RNA structure switch modulates EGFR-TKI resistance by controlling YRDC mRNA translation in an ELAVL1-dependent manner.
genetics & heredity
What problem does this paper attempt to address?